Trials / Terminated
TerminatedNCT02989649
Non-Interventional Study of the Use of Alogliptin and Alogliptin Fixed-Dose Combinations With Pioglitazone and With Metformin in Standard Clinical Practice
A Prospective, Non-Interventional Study of the Use of Alogliptin and Alogliptin Fixed-Dose Combinations With Pioglitazone and With Metformin in Standard Clinical Practice
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 593 (actual)
- Sponsor
- Takeda · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to observe alogliptin and alogliptin fixed-dose combinations (FDCs) utilization patterns, as well as clinical response to treatment with alogliptin or alogliptin FDCs, in standard clinical practice.
Detailed description
The drug being studied in this study is called alogliptin and alogliptin FDCs. Alogliptin and alogliptin FDCs is being researched to treat people who have diabetes mellitus type 2. This study will look at the glycosylated hemoglobin (HbA1c) level dynamics in participants with diabetes mellitus type 2. The study enrolled 593 patients. Alogliptin and alogliptin FDCs will be prescribed by the physician as part of participants' T2DM treatment program (independent of participation in this study). This multi-center study will be conducted in China. The overall duration of study for observation will be approximately 6 months, or up to loss to follow-up or death, whichever occurs first. Participants will make multiple visits to the clinic as per regular doctor's appointments.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Alogliptin | Alogliptin tablets |
| DRUG | Alogliptin FDC With Pioglitazone | Alogliptin FDC with pioglitazone tablets |
| DRUG | Alogliptin FDC With Metformin | Alogliptin FDC with metformin tablets |
Timeline
- Start date
- 2016-12-22
- Primary completion
- 2018-01-26
- Completion
- 2018-01-26
- First posted
- 2016-12-12
- Last updated
- 2019-04-19
- Results posted
- 2019-04-19
Locations
11 sites across 2 countries: China, Hong Kong
Source: ClinicalTrials.gov record NCT02989649. Inclusion in this directory is not an endorsement.